FR12C0041I2 - Analogues de somatostatine - Google Patents

Analogues de somatostatine

Info

Publication number: FR12C0041I2
Authority: FR; France
Prior art keywords: somatostatin analogs; somatostatin; analogs
Prior art date: 2000-08-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR12C0041C

Other languages

English (en)

French (fr)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-01

Filing date

2012-06-26

Publication date

2013-01-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9896782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-26 Application filed by Novartis AG filed Critical Novartis AG

2012-07-27 Publication of FR12C0041I1 publication Critical patent/FR12C0041I1/fr

2013-01-11 Application granted granted Critical

2013-01-11 Publication of FR12C0041I2 publication Critical patent/FR12C0041I2/fr

Status Active legal-status Critical Current

Links

NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Oncology (AREA)

FR12C0041C 2000-08-01 2012-06-26 Analogues de somatostatine Active FR12C0041I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0018891.2A GB0018891D0 (en)	2000-08-01	2000-08-01	Organic compounds
PCT/EP2001/008824 WO2002010192A2 (en)	2000-08-01	2001-07-30	Somatostatin analogues

Publications (2)

Publication Number	Publication Date
FR12C0041I1 FR12C0041I1 (2)	2012-07-27
FR12C0041I2 true FR12C0041I2 (fr)	2013-01-11

Family

ID=9896782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR12C0041C Active FR12C0041I2 (fr)	2000-08-01	2012-06-26	Analogues de somatostatine

Country Status (35)

Country	Link
US (5)	US7473761B2 (2)
EP (1)	EP1307486B1 (2)
JP (1)	JP3829118B2 (2)
KR (2)	KR100799394B1 (2)
CN (1)	CN1267451C (2)
AR (1)	AR034132A1 (2)
AT (1)	ATE393782T1 (2)
AU (2)	AU8977801A (2)
BE (1)	BE2012C026I2 (2)
BR (1)	BRPI0112859B8 (2)
CA (1)	CA2416293C (2)
CY (2)	CY1108547T1 (2)
CZ (1)	CZ302461B6 (2)
DE (1)	DE60133823T2 (2)
DK (1)	DK1307486T3 (2)
EC (1)	ECSP034456A (2)
ES (1)	ES2305104T3 (2)
FR (1)	FR12C0041I2 (2)
GB (1)	GB0018891D0 (2)
HU (1)	HU227812B1 (2)
IL (2)	IL153920A0 (2)
LU (1)	LU92024I2 (2)
MX (1)	MXPA03000991A (2)
MY (1)	MY138074A (2)
NO (2)	NO331093B1 (2)
NZ (1)	NZ523836A (2)
PE (1)	PE20020176A1 (2)
PL (1)	PL204161B1 (2)
PT (1)	PT1307486E (2)
RU (1)	RU2287533C2 (2)
SI (1)	SI1307486T1 (2)
SK (1)	SK287798B6 (2)
TW (1)	TWI282341B (2)
WO (1)	WO2002010192A2 (2)
ZA (1)	ZA200300406B (2)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds
US7189856B2 (en)	2001-12-28	2007-03-13	Gideon Shapiro	Non-peptide somatostatin receptor ligands
EP1572615B8 (en) *	2002-12-12	2010-07-14	Novartis AG	Process for the synthesis of peptides containing a 4-hydorxy-proline substructure
GB0229020D0 (en) *	2002-12-12	2003-01-15	Novartis Ag	Organic compounds
GB0300095D0 (en) *	2003-01-03	2003-02-05	Novartis Ag	Organic compounds
PE20050285A1 (es) *	2003-06-24	2005-06-09	Novartis Ag	Composicion farmaceutica que comprende analogos ciclicos de somatostatina
GB0314695D0 (en) *	2003-06-24	2003-07-30	Novartis Ag	Organic compounds
GB0318682D0 (en) *	2003-08-08	2003-09-10	Novartis Ag	Organic compounds
EP1522311A1 (fr)	2003-10-10	2005-04-13	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
MY158342A (en) *	2003-11-14	2016-09-30	Novartis Ag	Pharmaceutical composition
GB0412866D0 (en) *	2004-06-09	2004-07-14	Novartis Ag	Organic compounds
GB0428151D0 (en)	2004-12-22	2005-01-26	Novartis Ag	Organic compounds
GB0602639D0 (en)	2006-02-09	2006-03-22	Novartis Ag	Organic compounds
BRPI0712051A2 (pt) *	2006-06-08	2012-01-10	Novartis Ag	combinação de análogos de somatostatina com antagonista de receptor do hormÈnio de crescimento ou dopamina
US7697338B2 (en) *	2006-11-16	2010-04-13	Sandisk Corporation	Systems for controlled boosting in non-volatile memory soft programming
WO2008064570A1 (en) *	2006-11-28	2008-06-05	The University Of Hong Kong	The use of granulin-epithelin precursor (gep) antibodies for detection and suppression of hepatocellular carcinoma (hcc)
EP1941902A1 (en) *	2007-01-02	2008-07-09	Novartis AG	Use of Somatostatin analogs in cluster headache
EP2952522B1 (en)	2007-01-31	2019-10-30	Dana-Farber Cancer Institute, Inc.	Stabilized p53 peptides and uses thereof
AU2008232709C1 (en)	2007-03-28	2015-01-15	President And Fellows Of Harvard College	Stitched polypeptides
AR066677A1 (es)	2007-05-24	2009-09-02	Novartis Ag	Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.
WO2009009035A1 (en) *	2007-07-06	2009-01-15	Ipsen Pharma S.A.S.	Somatostatin analog and uses thereof
GB0719818D0 (en) *	2007-10-11	2007-11-21	Asterion Ltd	Growth hormone fusion polypeptides
MX2010005936A (es) *	2007-11-28	2010-06-15	Novartis Ag	Uso de analogos de somatostatina en meningioma.
EP2067786A1 (en)	2007-12-07	2009-06-10	ITALFARMACO S.p.A.	Novel non selective analogs of somatostatin
DK2225271T3 (da)	2007-12-03	2013-10-07	Italfarmaco Spa	Nye ikke-selektive somatostatin-analoger
US20090325863A1 (en) *	2008-06-13	2009-12-31	Kleinberg David L	Somatostatin analogs and IGF-I inhibition for breast cancer prevention
PL2310042T3 (pl)	2008-07-08	2013-05-31	Novartis Ag	Zastosowanie pasyreotydu do leczenia endogennej hipoglikemii hiperinsulinemicznej
EP2172189A1 (en)	2008-10-01	2010-04-07	Novartis AG	Pharmaceutical Compositions
EP2213307A1 (en)	2009-02-03	2010-08-04	Novartis AG	Injectable depot formulations
CN102176900B (zh)	2008-09-17	2017-09-26	克艾思马有限公司	药物组合物和相关的给药方法
UY33236A (es)	2010-02-25	2011-09-30	Novartis Ag	Inhibidores dimericos de las iap
KR20170058446A (ko)	2010-08-13	2017-05-26	에일러론 테라퓨틱스 인코포레이티드	펩티도미메틱 거대고리
WO2012074559A2 (en)	2010-12-02	2012-06-07	New York University	Treatment of non-proliferative cystic disease
UY33794A (es)	2010-12-13	2012-07-31	Novartis Ag	Inhibidores diméricos de las iap
US20130266590A1 (en)	2010-12-13	2013-10-10	Novartis Ag	Dimeric iap inhibitors
US20130035054A1 (en) *	2011-07-14	2013-02-07	Faceon Mobile	Phone with multi-portal access for display during incoming and outgoing call
WO2013019923A2 (en)	2011-08-02	2013-02-07	New York University	Methods for detecting progenitor cells and uses thereof
KR20140069235A (ko)	2011-09-27	2014-06-09	노파르티스 아게	돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
AR088392A1 (es)	2011-10-18	2014-05-28	Aileron Therapeutics Inc	Macrociclos peptidomimeticos
WO2013084138A1 (en)	2011-12-05	2013-06-13	Novartis Ag	Cyclic urea derivatives as androgen receptor antagonists
US9585959B2 (en)	2011-12-05	2017-03-07	Camurus Ab	Robust controlled-release formulations
CA2860676A1 (en)	2012-01-09	2013-07-18	Novartis Ag	Organic compositions to treat beta-catenin-related diseases
US8815926B2 (en)	2012-01-26	2014-08-26	Novartis Ag	Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
CA2862038C (en)	2012-02-15	2021-05-25	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
HK1205454A1 (en)	2012-02-15	2015-12-18	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
ES2834318T3 (es) *	2012-05-25	2021-06-17	Camurus Ab	Formulaciones de agonistas de receptores de la somatostatina
TWI633887B (zh)	2012-05-31	2018-09-01	大塚製藥股份有限公司	用於預防及／或治療多囊性腎臟病之藥物
BR112015009470A2 (pt)	2012-11-01	2019-12-17	Aileron Therapeutics Inc	aminoácidos dissubstituídos e seus métodos de preparação e uso
EP2922578B1 (en)	2012-11-21	2018-12-12	Serene, Llc	Tin-117m comprising somatostatin receptor binding compounds
BR112015018882B1 (pt)	2013-02-19	2021-09-14	Novartis Ag	Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
EP2970240B1 (en)	2013-03-14	2018-01-10	Novartis AG	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN105209460A (zh)	2013-03-14	2015-12-30	诺华股份有限公司	作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
WO2014147586A1 (en)	2013-03-22	2014-09-25	Novartis Ag	1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
CN103467575B (zh) *	2013-08-22	2016-03-02	深圳翰宇药业股份有限公司	一种帕西瑞肽的制备方法
CN103641894B (zh) *	2013-12-06	2015-10-28	深圳翰宇药业股份有限公司	一种治疗库欣病的多肽药物的制备方法
WO2015092634A1 (en)	2013-12-16	2015-06-25	Novartis Ag	1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JP6813357B2 (ja)	2013-12-19	2021-01-13	ノバルティスアーゲー	薬物送達システム
JO3517B1 (ar)	2014-01-17	2020-07-05	Novartis Ag	ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899493B (zh)	2014-01-17	2019-03-29	诺华股份有限公司	用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JP6523303B2 (ja)	2014-01-17	2019-05-29	ノバルティスアーゲー	Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
SG10201900002QA (en)	2014-01-24	2019-02-27	Dana Farber Cancer Institue Inc	Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en)	2014-01-31	2019-03-27	Novartis AG	Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en)	2014-03-14	2015-09-17	Novartis Ag	Antibody molecules to lag-3 and uses thereof
JP2017516779A (ja)	2014-05-28	2017-06-22	アイデニクス・ファーマシューティカルズ・エルエルシー	癌治療のためのヌクレオシド誘導体
WO2016049359A1 (en)	2014-09-24	2016-03-31	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh)	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
WO2016089830A1 (en)	2014-12-05	2016-06-09	Merck Sharp & Dohme Corp.	Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10442819B2 (en)	2014-12-05	2019-10-15	Merck Sharp & Dohme Corp.	Tricyclic compounds as inhibitors of mutant IDH enzymes
EP3226690B1 (en)	2014-12-05	2020-05-20	Merck Sharp & Dohme Corp.	Novel tricyclic compounds as inhibitors of mutant idh enzymes
WO2016094662A1 (en)	2014-12-10	2016-06-16	Chiasma Inc.	Oral octreotide administered in combination with other therapeutic agents
US20210317161A1 (en)	2014-12-19	2021-10-14	Auro Peptides Ltd	A process for the preparation of pasireotide
WO2016100882A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Combination therapies
HUE071943T2 (hu)	2015-02-03	2025-10-28	Amryt Endo Inc	Akromegália kezelése oktreotid orális alkalmazásával
HK1248603A1 (zh)	2015-03-10	2018-10-19	Aduro Biotech, Inc.	用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
US10253067B2 (en)	2015-03-20	2019-04-09	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
WO2016162127A1 (en) *	2015-04-08	2016-10-13	Polyphor Ag	Backbone-cyclized peptidomimetics
HK1252245A1 (zh)	2015-05-27	2019-05-24	Idenix Pharmaceuticals Llc	用於治疗癌症的核苷酸
ES2741746T3 (es)	2015-06-19	2020-02-12	Novartis Ag	Compuestos y composiciones para inhibir la actividad de SHP2
CN112625028B (zh)	2015-06-19	2024-10-29	诺华股份有限公司	用于抑制shp2活性的化合物和组合物
ES2824576T3 (es)	2015-06-19	2021-05-12	Novartis Ag	Compuestos y composiciones para inhibir la actividad de SHP2
US10556924B2 (en)	2015-06-22	2020-02-11	Biophore India Pharmaceuticals Pvt. Ltd.	Process for the preparation of pasireotide
GB201511790D0 (en)	2015-07-06	2015-08-19	Iomet Pharma Ltd	Pharmaceutical compound
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3878465A1 (en)	2015-07-29	2021-09-15	Novartis AG	Combination therapies comprising antibody molecules to tim-3
CR20180101A (es)	2015-08-13	2018-04-12	Merck Sharp & Dohme	Compuestos di-nucleóticos cíclicos como agonistas de sting
US11453697B1 (en)	2015-08-13	2022-09-27	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
EP3370768B9 (en)	2015-11-03	2022-03-16	Janssen Biotech, Inc.	Antibodies specifically binding pd-1 and their uses
US10538497B2 (en)	2015-12-15	2020-01-21	Merck Sharp & Dohme Corp.	Compounds as indoleamine 2,3-dioxygenase inhibitors
WO2017106656A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
JP6969800B2 (ja)	2016-05-04	2021-11-24	ジェノシアンスファルマ	増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
MX383856B (es)	2016-06-14	2025-03-14	Novartis Ag	Compuestos y composiciones para inhibir la actividad de shp2.
WO2018009466A1 (en)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10414747B2 (en)	2016-10-04	2019-09-17	Merck Sharp & Dohme Corp.	Benzo[b]thiophene compounds as sting agonists
EP3541825B1 (en)	2016-11-21	2026-04-01	Idenix Pharmaceuticals LLC	Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
US11021511B2 (en)	2017-01-27	2021-06-01	Janssen Biotech, Inc.	Cyclic dinucleotides as sting agonists
US11492367B2 (en)	2017-01-27	2022-11-08	Janssen Biotech, Inc.	Cyclic dinucleotides as sting agonists
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en)	2017-05-12	2022-10-11	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
US11312772B2 (en)	2017-08-04	2022-04-26	Merck Sharp & Dohme Corp.	Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
US11285131B2 (en)	2017-08-04	2022-03-29	Merck Sharp & Dohme Corp.	Benzo[b]thiophene STING agonists for cancer treatment
WO2019051469A1 (en)	2017-09-11	2019-03-14	Krouzon Pharmaceuticals, Inc.	Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
US11052065B2 (en)	2017-09-27	2021-07-06	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
US11180497B2 (en) *	2017-10-18	2021-11-23	Angex Pharmaceutical, Inc.	Cyclic compounds as immunomodulating agents
EP3703692B1 (en)	2017-11-01	2025-07-23	Merck Sharp & Dohme LLC	Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN111344287B (zh)	2017-11-14	2023-12-19	默沙东有限责任公司	作为吲哚胺2，3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物
EP3709986B1 (en)	2017-11-14	2023-11-01	Merck Sharp & Dohme LLC	Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2019118839A1 (en)	2017-12-15	2019-06-20	Janssen Biotech, Inc.	Cyclic dinucleotides as sting agonists
EP3727401A4 (en)	2017-12-20	2022-04-06	Merck Sharp & Dohme Corp.	CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3765006A4 (en)	2018-03-13	2022-02-23	Merck Sharp & Dohme Corp.	ARGINASE INHIBITORS AND METHODS OF USE
US10793557B2 (en)	2018-04-03	2020-10-06	Merck Sharp & Dohme Corp.	Sting agonist compounds
US11702430B2 (en)	2018-04-03	2023-07-18	Merck Sharp & Dohme Llc	Aza-benzothiophene compounds as STING agonists
EP3781687A4 (en)	2018-04-20	2022-02-09	Merck Sharp & Dohme Corp.	NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3810116B1 (en)	2018-05-31	2023-11-15	Merck Sharp & Dohme LLC	Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
EP3810615B1 (en)	2018-06-20	2026-01-28	Merck Sharp & Dohme LLC	Arginase inhibitors and methods of use
US10596278B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
US10596276B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
TW202517302A (zh)	2018-07-25	2025-05-01	法商高級催化劑應用品有限公司	穩定的、濃縮的放射性核種錯合物溶液
JP7542538B2 (ja)	2018-09-18	2024-08-30	ニカングセラピューティクス，インコーポレイテッド	Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体
WO2020068873A1 (en)	2018-09-25	2020-04-02	Black Diamond Therapeutics, Inc.	Tyrosine kinase inhibitor compositions, methods of making and methods of use
AU2019346550A1 (en)	2018-09-25	2021-04-22	Black Diamond Therapeutics, Inc.	Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
JP2022502385A (ja)	2018-09-29	2022-01-11	ノバルティスアーゲー	Ｓｈｐ２の活性を阻害するための化合物の製造方法
WO2020092183A1 (en)	2018-11-01	2020-05-07	Merck Sharp & Dohme Corp.	Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
EP3877366B1 (en)	2018-11-06	2026-01-28	Merck Sharp & Dohme LLC	Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
EP3886845B1 (en)	2018-11-28	2024-09-04	Merck Sharp & Dohme LLC	Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
US12240867B2 (en)	2018-12-18	2025-03-04	Merck Sharp & Dohme Llc	Arginase inhibitors and methods of use
US12281109B2 (en)	2019-04-04	2025-04-22	Merck Sharp & Dohme Llc	Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
WO2020260547A1 (en)	2019-06-27	2020-12-30	Rigontec Gmbh	Design method for optimized rig-i ligands
CA3149482A1 (en)	2019-08-02	2021-02-11	Mersana Therapeutics, Inc.	Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
EP4013749B1 (en)	2019-08-15	2026-03-11	Black Diamond Therapeutics, Inc.	Alkynyl quinazoline compounds
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN112724127B (zh)	2019-10-28	2023-02-17	中国科学院上海药物研究所	五元杂环氧代羧酸类化合物及其医药用途
WO2021113679A1 (en)	2019-12-06	2021-06-10	Mersana Therapeutics, Inc.	Dimeric compounds as sting agonists
WO2021126725A1 (en)	2019-12-17	2021-06-24	Merck Sharp & Dohme Corp.	Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
EP4087583B1 (en)	2020-01-07	2026-04-22	Merck Sharp & Dohme LLC	Arginase inhibitors and methods of use
WO2021195206A1 (en)	2020-03-24	2021-09-30	Black Diamond Therapeutics, Inc.	Polymorphic forms and related uses
WO2021202984A1 (en)	2020-04-02	2021-10-07	Mersana Therapeutics, Inc.	Antibody drug conjugates comprising sting agonists
CN115836054B (zh)	2020-05-06	2024-12-10	默沙东有限责任公司	Il4i1抑制剂和使用方法
WO2022140472A1 (en)	2020-12-22	2022-06-30	Nikang Therapeutics, Inc.	Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods
JP2024504932A (ja)	2021-01-13	2024-02-02	モンテローザセラピューティクス，インコーポレイテッド	イソインドリノン化合物
WO2022170052A1 (en)	2021-02-05	2022-08-11	Black Diamond Therapeutics, Inc.	Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
EP4323350A1 (en)	2021-04-14	2024-02-21	Monte Rosa Therapeutics AG	Isoindolinone compounds
WO2022219412A1 (en)	2021-04-14	2022-10-20	Monte Rosa Therapeutics Ag	Isoindolinone amide compounds useful to treat diseases associated with gspt1
WO2022227015A1 (en)	2021-04-30	2022-11-03	Merck Sharp & Dohme Corp.	Il4i1 inhibitors and methods of use
WO2023284730A1 (en)	2021-07-14	2023-01-19	Nikang Therapeutics, Inc.	Alkylidene derivatives as kras inhibitors
CN119053595A (zh)	2022-03-28	2024-11-29	尼坎治疗公司	作为细胞周期蛋白依赖性激酶2抑制剂的磺酰氨基衍生物
EP4536363A1 (en)	2022-06-08	2025-04-16	Nikang Therapeutics, Inc.	Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
JP2025528439A (ja) *	2022-08-30	2025-08-28	グラフトンセラピューティクスエスアエールエル	複数のソマトスタチン受容体サブタイプ選択性を有するハロゲン化ソマトスタチン類似体
JP2025537123A (ja)	2022-11-11	2025-11-14	ニカングセラピューティクス，インコーポレイテッド	ユビキチンプロテアソーム経路を介してサイクリン依存性キナーゼ２を分解するための２，５－置換ピリミジン誘導体を含有する二官能性化合物
TW202502311A (zh)	2023-03-29	2025-01-16	美商默沙東有限責任公司	Il4i1抑制劑及其使用方法
WO2025002263A1 (zh)	2023-06-30	2025-01-02	默沙东有限责任公司	治疗组合及其用途和治疗方法
WO2025072462A1 (en)	2023-09-27	2025-04-03	Nikang Therapeutics, Inc.	Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2025117616A1 (en)	2023-11-27	2025-06-05	Nikang Therapeutics, Inc.	Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025117981A1 (en)	2023-12-02	2025-06-05	Nikang Therapeutics, Inc.	Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2025212828A1 (en)	2024-04-03	2025-10-09	Nikang Therapeutics, Inc.	Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025240536A1 (en)	2024-05-15	2025-11-20	Nikang Therapeutics, Inc.	Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3863008A (en)	1973-06-11	1975-01-28	American Home Prod	Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en)	1979-10-31	1984-10-19	Merck & Co Inc	Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en)	1980-07-09	1981-10-06	E. R. Squibb & Sons, Inc.	Lyophilized hydrocolloio foam
US4612386A (en) *	1980-09-16	1986-09-16	The Dow Chemical Company	Process for making esters
US4505897A (en)	1983-04-18	1985-03-19	The Administrators Of The Tulane Educational Fund	Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en)	1985-06-17	1986-09-16	Merck & Co., Inc.	Cyclic hexapeptide somatostatin analogs
CA2012115C (en)	1989-03-15	2001-07-03	Biomeasure, Inc.	Iodinated somatostatins
JP2882679B2 (ja)	1989-04-26	1999-04-12	ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド	線状ソマトスタチン類似体
US5620675A (en)	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
US5716596A (en)	1992-06-23	1998-02-10	Diatide, Inc.	Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
ATE337338T1 (de)	1993-06-23	2006-09-15	Diatide Inc	Radioaktiv-markierte peptidderivate des somatostatins zur bildformenden und therapeutischen verwendung
EP0788509B1 (en)	1993-08-09	2003-05-28	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Therapeutic peptide derivatives
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
MY147327A (en) *	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
GB9513224D0 (en) *	1995-06-29	1995-09-06	Sandoz Ltd	Organic compounds
IT1277391B1 (it)	1995-07-28	1997-11-10	Romano Deghenghi	Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
AU2764797A (en)	1996-05-14	1997-12-05	Novo Nordisk A/S	Somatostatin agonists and antagonists
US6355613B1 (en)	1996-07-31	2002-03-12	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
CA2246791A1 (en)	1998-09-01	2000-03-01	Alison Buchan	Treatment of endothelium with somatostatin analogues
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds

2000
- 2000-08-01 GB GBGB0018891.2A patent/GB0018891D0/en not_active Ceased
2001
- 2001-07-26 PE PE2001000760A patent/PE20020176A1/es active IP Right Grant
- 2001-07-26 TW TW090118314A patent/TWI282341B/zh active
- 2001-07-30 PL PL358718A patent/PL204161B1/pl unknown
- 2001-07-30 CZ CZ20030288A patent/CZ302461B6/cs unknown
- 2001-07-30 RU RU2003105817/04A patent/RU2287533C2/ru active Protection Beyond IP Right Term
- 2001-07-30 ES ES01969555T patent/ES2305104T3/es not_active Expired - Lifetime
- 2001-07-30 DK DK01969555T patent/DK1307486T3/da active
- 2001-07-30 JP JP2002515921A patent/JP3829118B2/ja not_active Expired - Lifetime
- 2001-07-30 NZ NZ523836A patent/NZ523836A/en not_active IP Right Cessation
- 2001-07-30 WO PCT/EP2001/008824 patent/WO2002010192A2/en not_active Ceased
- 2001-07-30 KR KR1020067005526A patent/KR100799394B1/ko not_active Expired - Lifetime
- 2001-07-30 MX MXPA03000991A patent/MXPA03000991A/es active IP Right Grant
- 2001-07-30 BR BRPI0112859A patent/BRPI0112859B8/pt not_active IP Right Cessation
- 2001-07-30 CN CNB018136869A patent/CN1267451C/zh not_active Expired - Lifetime
- 2001-07-30 AU AU8977801A patent/AU8977801A/xx active Pending
- 2001-07-30 MY MYPI20013578A patent/MY138074A/en unknown
- 2001-07-30 AR ARP010103642A patent/AR034132A1/es active IP Right Grant
- 2001-07-30 DE DE60133823T patent/DE60133823T2/de not_active Expired - Lifetime
- 2001-07-30 AT AT01969555T patent/ATE393782T1/de active
- 2001-07-30 SI SI200130836T patent/SI1307486T1/sl unknown
- 2001-07-30 SK SK121-2003A patent/SK287798B6/sk not_active IP Right Cessation
- 2001-07-30 IL IL15392001A patent/IL153920A0/xx unknown
- 2001-07-30 HU HU0300684A patent/HU227812B1/hu active Protection Beyond IP Right Term
- 2001-07-30 US US10/343,288 patent/US7473761B2/en active Active
- 2001-07-30 PT PT01969555T patent/PT1307486E/pt unknown
- 2001-07-30 EP EP01969555A patent/EP1307486B1/en not_active Expired - Lifetime
- 2001-07-30 KR KR10-2003-7001435A patent/KR20030033008A/ko not_active Ceased
- 2001-07-30 CA CA2416293A patent/CA2416293C/en not_active Expired - Lifetime
- 2001-07-30 AU AU2001289778A patent/AU2001289778B2/en active Active
2003
- 2003-01-13 IL IL153920A patent/IL153920A/en active Protection Beyond IP Right Term
- 2003-01-15 ZA ZA200300406A patent/ZA200300406B/xx unknown
- 2003-01-29 EC EC2003004456A patent/ECSP034456A/es unknown
- 2003-01-30 NO NO20030484A patent/NO331093B1/no not_active IP Right Cessation
2008
- 2008-07-29 CY CY20081100789T patent/CY1108547T1/el unknown
- 2008-11-05 US US12/265,135 patent/US7939625B2/en not_active Expired - Fee Related
2011
- 2011-03-16 US US13/048,935 patent/US9035021B2/en not_active Expired - Lifetime
- 2011-03-16 US US13/048,932 patent/US8822637B2/en not_active Expired - Lifetime
2012
- 2012-06-20 LU LU92024C patent/LU92024I2/fr unknown
- 2012-06-21 BE BE2012C026C patent/BE2012C026I2/fr unknown
- 2012-06-26 FR FR12C0041C patent/FR12C0041I2/fr active Active
- 2012-06-29 NO NO2012012C patent/NO2012012I2/no not_active IP Right Cessation
- 2012-06-29 CY CY2012018C patent/CY2012018I2/el unknown
2015
- 2015-04-08 US US14/681,226 patent/US20150218223A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1446229A (zh)	2003-10-01
CY1108547T1 (el)	2014-04-09
SI1307486T1 (sl)	2008-08-31
GB0018891D0 (en)	2000-09-20
ES2305104T3 (es)	2008-11-01
HUP0300684A2 (hu)	2003-09-29
US9035021B2 (en)	2015-05-19
NO20030484D0 (no)	2003-01-30
HK1057051A1 (en)	2004-03-12
EP1307486B1 (en)	2008-04-30
WO2002010192A3 (en)	2002-09-19
NO2012012I2 (no)	2012-07-30
MY138074A (en)	2009-04-30
KR20060035809A (ko)	2006-04-26
CY2012018I1 (el)	2015-10-07
AU2001289778B2 (en)	2005-02-03
WO2002010192A9 (en)	2002-10-17
EP1307486A2 (en)	2003-05-07
KR100799394B1 (ko)	2008-01-30
HUP0300684A3 (en)	2004-08-30
AR034132A1 (es)	2004-02-04
US20110166320A1 (en)	2011-07-07
CZ2003288A3 (cs)	2003-05-14
PT1307486E (pt)	2008-07-31
BRPI0112859B8 (pt)	2021-05-25
DK1307486T3 (da)	2008-08-25
WO2002010192A2 (en)	2002-02-07
SK1212003A3 (en)	2003-08-05
US8822637B2 (en)	2014-09-02
RU2287533C2 (ru)	2006-11-20
US20090069225A1 (en)	2009-03-12
US7473761B2 (en)	2009-01-06
PL204161B1 (pl)	2009-12-31
HU227812B1 (hu)	2012-03-28
IL153920A (en)	2010-12-30
ECSP034456A (es)	2003-03-10
KR20030033008A (ko)	2003-04-26
MXPA03000991A (es)	2003-06-09
BE2012C026I2 (2)	2020-12-15
LU92024I2 (fr)	2012-08-20
CY2012018I2 (el)	2015-10-07
JP2004505095A (ja)	2004-02-19
AU8977801A (en)	2002-02-13
US20150218223A1 (en)	2015-08-06
US20110172157A1 (en)	2011-07-14
CA2416293C (en)	2011-05-10
NZ523836A (en)	2004-08-27
DE60133823T2 (de)	2009-05-20
ATE393782T1 (de)	2008-05-15
IL153920A0 (en)	2003-07-31
DE60133823D1 (de)	2008-06-12
SK287798B6 (sk)	2011-10-04
NO2012012I1 (no)	2012-06-29
JP3829118B2 (ja)	2006-10-04
US20050014686A1 (en)	2005-01-20
PE20020176A1 (es)	2002-03-26
CN1267451C (zh)	2006-08-02
CZ302461B6 (cs)	2011-06-01
CA2416293A1 (en)	2002-02-07
NO331093B1 (no)	2011-10-03
NO20030484L (no)	2003-03-19
PL358718A1 (en)	2004-08-09
FR12C0041I1 (2)	2012-07-27
US7939625B2 (en)	2011-05-10
BRPI0112859B1 (pt)	2016-03-01
TWI282341B (en)	2007-06-11
ZA200300406B (en)	2004-04-02
BR0112859A (pt)	2003-07-01

Publication	Publication Date	Title
FR12C0041I2 (fr)	2013-01-11	Analogues de somatostatine
EP1353683A4 (en)	2004-05-12	ANALOGS BY GHRELIN
NO20032101D0 (no)	2003-05-09	Apoliprotein analoger
DK1124779T3 (da)	2005-06-06	D-vitaminanaloge forbindelser
GB0128526D0 (en)	2002-01-23	Nucleotide analogues
NO992532D0 (no)	1999-05-26	Heptapeptid oksytocinanaloger
EP0996458A4 (en)	2001-05-02	SANDRAMYCIN ANALOG
PL364768A1 (pl)	2004-12-13	Analogi witaminy D
DK1401863T3 (da)	2009-05-25	Kimære somatostatin-dopamin-analoge
AU2002360487A8 (en)	2003-06-17	Acyclovir-peptide analogs
EP1594529A4 (en)	2008-01-16	GLP-1 Analogs
EP1651662A4 (en)	2009-07-01	ANTAGONISTIC ANALOGUE OF GH-RH (2003)
EP1397150A4 (en)	2005-01-26	Somatostatin agonists
DK1200399T3 (da)	2004-07-19	Vitamin D3-analoger
DK1235824T3 (da)	2004-06-28	D-vitaminanaloge forbindelser
NO20006320D0 (no)	2000-12-12	Cykliske somatostatin-analoger
FR2833258B1 (fr)	2004-08-27	Analogues de la vitamine d
EP1549309A4 (en)	2006-05-17	SOMATOSTATIN ANALOG CONNECTIONS
DE60226419D1 (de)	2008-06-19	Somatostatin-antagonisten
NO20041066L (no)	2004-06-14	Hydroksyeikosensyre-analoger
GB0022877D0 (en)	2000-11-01	Analogues
EP1211241A4 (en)	2004-10-27	ANALOG OF PROSTAGLANDIN E
DK1137667T3 (da)	2005-02-14	GLP-1-analoger
DK1143992T3 (da)	2005-03-07	Terapeutisk sammensætninger indeholdende glutathionanaloge
SE0003187D0 (sv)	2000-09-08	Novel enkephalin analogues